Corona Remedies IPO Creates Buzz as Grey-Market Premium Shoots Up to ₹365 Ahead of Subscription Opening on 8 December

With investor interest rising by the day, the IPO is set to draw attention from both seasoned and first-time market participants.

IPO Price Band and Valuation Snapshot

Corona Remedies has fixed its IPO price band at ₹1,008–₹1,062 per share, placing the company’s valuation close to ₹6,500 crore at the upper end. The issue size stands at ₹655.37 crore, but it is important to note that the entire offering is an Offer for Sale (OFS).

That means the company will not receive any fresh capital through this IPO. Instead, existing shareholders—primarily private equity firm ChrysCapital—will offload a part of their stake. For investors, however, the offer still presents an opportunity to participate in a company that has built a strong niche in branded formulations.

Key Dates: Subscription Window & Listing Timeline

The public issue is scheduled for a three-day subscription period:

• Opens: 8 December
• Closes: 10 December

Anchor investors will get early access on 5 December, as per the standard SEBI guidelines that allow institutional participation one working day before the IPO opens for retail investors.

If regulatory approvals come through smoothly, Corona Remedies is expected to make its stock market debut on 15 December.

Grey Market Premium Surges—What It Means

According to grey-market data tracked by Investorgain.com, Corona Remedies’ shares were trading at around ₹1,392 on Thursday, 4 December. This translates into a premium of ₹365 over the IPO’s upper price band, implying potential listing gains of about 35% if the sentiment stays intact.

While GMP is not an official indicator and does not guarantee returns, it often mirrors market mood and early interest among high-risk investors. The strong premium suggests that the IPO has caught the attention of traders expecting a robust listing.

About Corona Remedies: A Growing Pharma Force

Headquartered in Ahmedabad, Corona Remedies is a pharmaceutical formulations company with an expanding footprint in some of India’s fastest-growing therapeutic categories. Its product portfolio spans:

• Women’s health
• Cardio-metabolic care (including heart ailments and diabetes)
• Chronic lifestyle diseases

By focusing on branded prescription products and high-growth therapy areas, the company has steadily strengthened its presence in the domestic healthcare market. Its partnerships, product pipeline, and diversification strategy have further added to investor confidence.

Corona Remedies’ growth story fits well into the broader trend of rising demand for chronic and lifestyle-related medicines in India—a segment that continues to outpace the broader pharma market.

Wakefit Innovations: Another IPO Going Live on the Same Day

Adding to the excitement, Wakefit Innovations Ltd., the well-known furniture and home-solutions brand, will also open its IPO on 8 December—the same day as Corona Remedies.

Wakefit IPO Highlights

• Price Band: ₹185–₹195
• Face Value: ₹1
• Minimum Lot: 76 shares (and multiples of 76 thereafter)
• Anchor Bidding: 5 December
• Retail Window: 8–10 December

Wakefit has grown from a mattress start-up into a full-fledged online furniture ecosystem. Its rapid expansion, brand visibility, and digital-first model have made this IPO another attractive proposition for investors keeping an eye on consumer-tech businesses.

Two Different Stories, One Busy IPO Week

With Corona Remedies from the healthcare space and Wakefit Innovations from the consumer/home-solutions sector, 8–10 December promises a diverse set of opportunities for investors. One is backed by the defensive, recession-resistant pharma industry; the other is riding India’s booming online retail and home-improvement wave.

Market watchers expect high subscription levels if current sentiment holds, especially with the strong GMP action for Corona Remedies already setting the tone.